1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Heart rhythm conditions

Heart rhythm conditions

  • Register as a stakeholder

Research Recommendations

  • Cognitive behavioural therapy for people with atrial fibrillation:- What is the clinical and cost effectiveness of cognitive ...
    September 2014
  • Rate control drug treatment for people aged 75 and over with atrial fibrillation:- What is the comparative effectiveness of t...
    October 2014
  • Case volume as an indicator of quality for people offered left atrial catheter ablation:- What is the effect of case volume o...
    October 2014
  • Non-vitamin K antagonist oral anticoagulants:- Do people with atrial fibrillation whose anticoagulant control is poor, or is ...
    October 2014
  • Stroke risk assessment:- Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillati...
    October 2014
  • Further research for percutaneous endoscopic catheter laser balloon pulmonary vein isolation for atrial fibrillation (AF) sho...
  • NICE encourages clinicians to enter patients into research studies with the particular aims of guiding selection of patients ...
    May 2012
  • There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxab...
    February 2013

Shared Learning

  • A programme to introduce annual GP review for patients on warfarin with atrial fibrillation who display poor anticoagulation control
    January 2017
  • Insights from the NHS: the adoption of self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor) for atrial fibrillation and heart valve disease
    April 2016
  • Reducing the risk of stroke in AF: using the NICE PDA with patients not currently treated with anticoagulants
    March 2016
  • Improving anticoagulation in patients with atrial fibrillation using the GRASP AF audit tool (part of the GRASP suite of tools delivered by PRIMIS in partnership with NHS England)
    February 2016
  • A Retrospective analysis determining whether a significant proportion of diagnoses of Atrial Fibrillation are made in the Emergency Department
    January 2015
  • The One Stop Atrial Fibrillation Clinic in Llanelli
    May 2014
  • Atrial Fibrillation Community - Working together to save and improve lives
    May 2014
  • Improving anticoagulation in atrial fibrillation (AF): Primary care interventions
    May 2014
  • Community delivered and Hospital supported Cardiovascular Services - 'A package of support'
    May 2014
  • Medicines Optimisation: Stroke prevention in atrial fibrillation in practice
    May 2014

Do not do

  • Do not routinely perform TTE (transthoracic echocardiography) solely for the purpose of further stroke risk stratification in people with atrial fibrillation for whom the need to initiate anticoagulation therapy has already been agreed on appropriate clinical criteria (see section 1.4 Assessment of stroke and bleeding risks and section 1.5 Interventions to prevent stroke).
    June 2014
  • Do not withhold anticoagulation solely because the person is at risk of having a fall.
    June 2014
  • Do not offer stroke prevention therapy to people aged under 65 years with atrial fibrillation and no risk factors other than their sex (that is, very low risk of stroke equating to a CHA2DS2-VASc score of 0 for men or 1 for women).
    June 2014
  • Do not offer aspirin monotherapy solely for stroke prevention to people with atrial fibrillation.
    June 2014
  • Do not offer LAAO (left atrial appendage occlusion) as an alternative to anticoagulation unless anticoagulation is contraindicated or not tolerated.
    June 2014
  • Do not offer amiodarone for long-term rate control.
    June 2014
  • Do not offer class 1c antiarrhythmic drugs such as flecainide or propafenone to people with known ischaemic or structural heart disease.
    June 2014
  • Do not offer magnesium or a calcium-channel blocker for pharmacological cardioversion.
    June 2014
  • In people undergoing cardiothoracic surgery do not offer digoxin.
    June 2014
  • Guidance
  • Resources
    • Savings and productivity
    • Local practice
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Savings and productivity
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Guidance app

  • Android
  • iOS

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • Public involvement
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions

Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.